ADT Pharma

ADT Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule drugs for the treatment of RAS-mutant cancers. The company's lead program, ADT-007, is a potent, orally bioavailable pan-RAS inhibitor that targets all major RAS isoforms (KRAS, NRAS, and HRAS) and their common mutations. This approach is designed to overcome the limitations of isoform-specific inhibitors and provide a broader therapeutic option for patients with pancreatic, colorectal, and lung cancers. Founded on research from the University of South Alabama's Mitchell Cancer Institute, ADT Pharmaceuticals leverages its expertise in medicinal chemistry and oncology to advance a pipeline of candidates targeting critical signaling pathways in cancer progression.